先健科技(01302.HK)獲工業大麻種植許可與美資達合作框架
先健科技(01302.HK)公布,與美國納斯達克上市公司索倫托藥業達成合作框架協議書,暨雙方啟動在中國設立深圳雲麻工業大麻的合作後,進一步合作在美國設立合資---Scintilla Health以針對亞洲以外的全球市場進行CBD(水溶性大麻二酚)及其他水溶性大麻素產品的研發、生產以及商業化;索倫托藥業分別獨家排他長期無償許可深圳雲麻在亞洲地區、Scintilla Health在亞洲以外的其他區域,使用其擁有自主知識產權的水溶性配方技術進行水溶大麻素產品的研發、生產和商業化,惟日本區域的商業化安排由雙方另行商榷。
同時,公司與索倫托藥業合資設立的深圳雲麻之控股附屬雲南麻省已獲得種植許可證及加工前置許可,獲准開展工業大麻的種植以及籌建工業大麻花葉萃取加工生產線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.